A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Clinical trial NCT03839771 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03839771
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndrome With Excess Blasts-2

Start date: 2019-03-01
Primary completion: 2027-04-17
Enrollment: 968

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.